FR-167356 

FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC₅₀ values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss^[1].

FR-167356 (200 mg/kg; p.o.; daily, for 10 days; male C57BL/6 mice with B16-F10 xenografts) inhibits tumor growth and reduces MMP9 expression^[1].
FR-167356 (200 mg/kg; p.o.; daily, for 10 days; male C57BL/6 mice with B16-F10 xenografts) reduces bone metastasis compared to untreated group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

378.25

C₁₉H₁₇Cl₂NO₃

174185-16-1

O=C(NC1=C(OC(C)=C2C(C)(O)C)C2=CC=C1)C3=C(Cl)C=CC=C3Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nishisho T, et, al. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011 Jul;9(7):845-55.  [Content Brief]

  [2]. Niikura K, et, al. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005 Sep;20(9):1579-88.  [Content Brief]